Lv6
2110 积分 2022-07-19 加入
Heterozygous human JAK2V617F activates AhR to drive essential thrombocythemia and promote thrombosis
27天前
已完结
Discovery and Preclinical Characterization of INCB018424, a Selective JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders
1个月前
已完结
Discovery of Novel CBP/p300 and BRD4 Dual-Target PROTACs with Potent Antitumor Activity in Prostate Cancer
1个月前
已完结
Discovery of Cdc20/Hsp90 Dual-Target Inhibitors with Potent Antitumor Activity for Therapy of Acquired Resistant Melanoma
1个月前
已完结
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study
1个月前
已完结
Prevalence of class I–III BRAF mutations among 114,662 cancer patients in a large genomic database
1个月前
已完结
Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms
2个月前
已完结
New Binding Sites for JAK2 Inhibition in Myeloproliferative Neoplasms: Structural Insights, Therapeutic Potential, and Future Directions
2个月前
已完结
Design and Development of DNA Damage Chemical Inducers of Proximity for Targeted Cancer Therapy
2个月前
已完结
Targeting KRAS in cancer
2个月前
已完结
皖公网安备34019202002308
